- Home
- APDN vs CANF Comparison
APDN vs CANF Comparison
Compare APDN & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APDN
- CANF
- Stock Information
- Founded
- APDN 1983
- CANF 1994
- Country
- APDN United States
- CANF Israel
- Employees
- APDN N/A
- CANF N/A
- Industry
- APDN Other Consumer Services
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- APDN Consumer Discretionary
- CANF Health Care
- Exchange
- APDN Nasdaq
- CANF Nasdaq
- Market Cap
- APDN 9.4M
- CANF 9.4M
- IPO Year
- APDN N/A
- CANF N/A
- Fundamental
- Price
- APDN $0.19
- CANF $1.55
- Analyst Decision
- APDN Strong Buy
- CANF Strong Buy
- Analyst Count
- APDN 1
- CANF 2
- Target Price
- APDN $1.50
- CANF $14.00
- AVG Volume (30 Days)
- APDN 5.7M
- CANF 138.1K
- Earning Date
- APDN 02-13-2025
- CANF 02-03-2025
- Dividend Yield
- APDN N/A
- CANF N/A
- EPS Growth
- APDN N/A
- CANF N/A
- EPS
- APDN N/A
- CANF N/A
- Revenue
- APDN $3,431,420.00
- CANF $667,000.00
- Revenue This Year
- APDN $54.72
- CANF $409.56
- Revenue Next Year
- APDN N/A
- CANF N/A
- P/E Ratio
- APDN N/A
- CANF N/A
- Revenue Growth
- APDN N/A
- CANF N/A
- 52 Week Low
- APDN $0.12
- CANF $1.29
- 52 Week High
- APDN $14.40
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- APDN 47.03
- CANF 43.14
- Support Level
- APDN $0.21
- CANF $1.55
- Resistance Level
- APDN $0.25
- CANF $1.64
- Average True Range (ATR)
- APDN 0.03
- CANF 0.10
- MACD
- APDN -0.00
- CANF 0.01
- Stochastic Oscillator
- APDN 26.75
- CANF 17.14
About APDN Applied DNA Sciences Inc.
Applied DNA Sciences Inc is a biotechnology company developing and commercializing technologies to produce and detect deoxyribonucleic acid (DNA) nd ribonucleic acid (RNA). The company operates in three business segments- Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. It generates majority of its revenue from the MDx Testing Services which is involved in performing and developing clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The company provides its products and services under the brand of Applied DNA Sciences, SigNature molecular tags, SigNature T molecular tags, fiberTyping, SigNify and others.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).